Nanopath, a point-of-care diagnostics company enabling laboratory-quality molecular testing in minutes, has announced the close of a $25 million Series B financing round, which includes $2 million in non-dilutive grant financing. The round is co-led by Norwest and SV Health Investors' MedTech Convergence Fund, alongside strategic participation from the Labcorp Venture Fund. New and existing investors also participated, including Elderberry Ventures, GingerBread Capital, and Alumni Ventures.

Nanopath is a women-led company dedicated to improving health equity worldwide, starting with women's health. Nanopath's proprietary molecular diagnostic testing platform takes a radically new approach to how clinicians characterize human health. The company's novel biosensing technology has the potential to enable fast, high-complexity testing at the point-of-care, rather than in centralized laboratories. The company is headquartered in Cambridge, Mass., at The Engine built by MIT, a premier facility for high-potential, tough-tech start-ups. Founded in 2020, Nanopath has raised more than $46 million, and is backed by Norwest, the Medtech Convergence Fund, an SV Health Investors Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures and the Labcorp Venture Fund.